Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Shareholder Meeting (May 2023)
14 slides from Imricor Medical Systems's shareholder meeting presentation, May 2023
Slide 1: Annual General Meeting May 2023
rsonal use only Annual General Meeting May 2023 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to place undue reliance on
Slide 3: Imricor's Board of Directors and CFO
ImricorÕs Board of Directors and CFO rsonal use only Steve Wedan Mark Tibbles Anita Messal Peter McGregor Jonathon Gut Executive Chair, Deputy Chair, Non-Executive Director Non-Executive Director CFO President, & CEO Non-Executive Director INVESTOR PRESENTATION | 3
Slide 4: Chair's Address
rsonal use only ChairÕs Address
Slide 5: Mission
Mission rsonal use only Mission To establish a new standard of care for the $US6bn1 cardiac ablation market with real-time iCMR procedures. Number of iCMR Sites Variety of Procedures Breadth of Geographies 1. Estimated based on data from United States, Europe, ANZ INVESTOR PRESENTATION | 5
Slide 6: Key message
Key message rsonal use only Primary Drivers of Value Additional Drivers of Value • Expand indications to complex • Grow number of active iCMR sites procedures where iCMR adds the most value • Focus on new iCMR sites owned and • Ventricular tachycardia (VT) controlled by cardiology and atrial fibrill
Slide 7: 2022 Highlights
2022 Highlights Sites Products New Funding Secured • 9 active sites across Europe • Second generation ablation • Secured a US$1.5 million loan rsonal use only catheter submitted for approval under the North Dakota • Contracted 3 new sites across in Europe Commerce DepartmentÕs Europe Innovation Tech
Slide 8: NorthStar 3D Mapping System
NorthStar 3D Mapping System Creating the central core of every iCMR practice by harnessing the value MRI brings rsonal use only ¥ System used successfully in human setting with Siemens MRI platform ¥ Development started in 2023 to interface with GE HealthCare MRI platform ¥ Working through the SIGNE
Slide 9: Business Update and Outlook
rsonal use only Business Update and Outlook
Slide 10: Clinical trials update
Clinical trials update Ventricular Tachycardia (VT) Ð Atrial Flutter(AFL) Ð VISABL-AFL Trial rsonal use only VISABL-VT Trial (EU) (US) • Testing, and documentation completed • Received an approved Investigational for NorthStar to be added to the VISABL- Device Exemption (IDE) from the US Food VT stu
Slide 11: Other FY2023 updates
Other FY2023 updates ¥ Twice as many procedures performed in Q1 2023 compared to Q4 2022 rsonal use only ¥ Entered into a Master Services Agreement (MSA) with GE Healthcare in April, where GE Healthcare will pay Imricor to develop to the hardware and software required to make NorthStar operate with
Slide 12: Path to significant scale
Path to significant scale Growing with Expanding Addressing Today new rsonal use only Geographies Entire Market Indications iCMR Atrial Flutter iCMR Ventricular Tachycardia FDA approval in US Atrial Fibrillation Ablations (AFL) in the EU Ablations (VT) in the EU Ablations (Afib) worldwide • Establis
Slide 13: Our focus for the year ahead
Our focus for the year ahead rsonal use only 1 2 3 Commercialisation VISABL-VT Trial VISABL-AFL Trial • Activating sites (EU) (US) • Increasing procedure • Commence trial • Commence trial volumes across active • Expected to catalyse • First major step into the sites market as value of VT is signific
Slide 14: Contact Information
Contact Information rsonal use only Investors & Australian Media: Simon Hinsley NWR Communications Email: simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Vice President, Marketing an
Imricor Medical Systems — Shareholder Meeting (May 2023) on 6ix